Skip to main content

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie policy for more information on the use of cookies on this website.

Top
  • COVID-19
    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
  • Products
    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers
Home

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers

Main Navigation

  • COVID-19
    Vaccine Development
    Vaccine Development

    Accelerating global operations to manage and process samples critical to vaccine development.

    Azenta Life Sciences Virtual Booth
    Azenta Life Sciences Virtual Booth

    The exhibition experience to your desktop or mobile device

    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
    Resources Center

    Learn about sample management best practices, gain advice from industry leaders, gain access to global regulatory and logistics guidelines and find simple support tools that can help you make better sample management decisions.

    Resources Center
  • Products
    Azenta Sample Pack and Catalog
    Sample Tube Pack Request

    Improve sample tracking, ensure sample integrity and drive process efficiency with Azenta Sample Storage Tubes. Explore the range, and select the best tube for your workflow.

    Low DNA Binding Microplates
    Low Binding Microplates

    Ultra low DNA binding microplates made from PP, fit for Next Generation Sequencing (NGS) and other sensitive applications with ultra-low DNA input. Off the shelf options. Custom solutions on request.

    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    Clinical Trial Management
    Clinical Trial Management

    Life science organizations must collect and manage large numbers of research samples to bring a new therapeutic or diagnostic to market. This is a complex process.

    Sample Preparation & Lab Analytical Services
    Genomics Services by GENEWIZ

    Comprehensive genomics services provide end to end solutions and best-in-class data quality from the trusted experts in genomics.

    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    disaster recovery
    How Safe Are Your Samples?

    Plastic storage tubes are used in laboratories worldwide to store biological and chemical samples.

    Product Support Plans
    Product Support Plans

    Azenta  Life Sciences' world class service team is committed to ensuring you meet your business objectives by providing a flexible portfolio of service products designed to optimize up-time and productivity.

    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    Putting a Sample Kit in an envelope
    Quality Assurance Certifications

    Azenta Life Sciences has established, documented, implemented and currently maintains a quality management system that fulfills the needs of customers.

    About Azenta Life Sciences
    About Azenta Life Sciences

    We are Azenta Life Sciences. We provide unrivaled sample exploration and management solutions to help our customers accelerate discovery, development and delivery.

    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Blog

You are here

  • Home
  • Blog
  • Fine-Tuning mRNA Structure for Better mRNA Therapies

Fine-Tuning mRNA Structure for Better mRNA Therapies

October 19, 2022

mRNA translated in the cytosol

 

The structure of mRNA has been known for decades, but only in recent years have researchers unlocked its potential for therapeutic development. With the right delivery vehicle, mRNA products can replace defective proteins in the cell, generate antigens for immunization (e.g., COVID vaccines), or edit the genome via CRISPR technology. Let’s review the structural features of a functional mRNA molecule and discuss how to optimize these for therapeutic applications.

 

mRNA Structure

For mRNA therapies, the objective is robust expression of the encoded protein. Transcripts that are efficiently translated and degraded slowly fare the best. Going from 5’ to 3’, components of an mRNA molecule include the 5’ cap, 5’ untranslated region (UTR), coding sequence, 3’ UTR, and poly(A) tail (Figure 1). Collectively they influence the amount of protein synthesized by dictating the transcript’s stability and translational efficiency in the cytosol. In the next few sections, we’ll examine each element.

mRNA structure and interaction with translation machinery

Figure 1. Structure of mRNA. (A) Anatomy of a eukaryotic transcript. (B) In the cytosol, the 5’ end of the transcript binds to the preinitiation complex, which recruits the ribosome to start translation. Poly(A) binding proteins at the 3’ end interact with the preinitiation complex, forming a loop structure.

 

5’ cap

Description: A modified guanosine (7-methylguanylate, abbreviated as m7G) attached to the 5’ end of the RNA molecule via a 5’ to 5’ triphosphate linkage.

Function in the cytosol: The 5’ cap binds to the preinitiation complex to promote translation. Also, its unusual attachment to the mRNA prevents degradation by 5’ to 3’ exonucleases.

Considerations for therapies: Nucleotide modifications adjacent to the 5’ cap are common in mammals. Methylation of the first nucleotide after the 5’ to 5’ triphosphate linkage, represented as m7GpppNm, creates a structure called cap 1. In contrast, mRNA with cap 0 (m7Gppp) lack this modification. Cap 1 is important for differentiating self from non-self RNA and thus evading the innate immune response1. Nucleotide analogues can be used during in vitro transcription to create cap 1 structures.

 

5’ Untranslated Region (5’ UTR)

Description: Nucleotide sequence upstream of start codon, excluding the 5’ cap.

Function in the cytosol: The 5’ UTR can regulate initiation of translation by interacting with the preinitiation complex or RNA-binding proteins. Stable secondary structures in the 5’ UTR, such as hairpins, can inhibit ribosome binding or scanning, lowering protein expression2.

Considerations for therapies: UTR sequences from highly expressed genes are typically used for mRNA therapies. The most popular are derived from the alpha and beta globin genes3. Adding an internal ribosomal entry site (IRES) to the 5’ UTR has been shown to boost translation efficiency. It can recruit the ribosome independently of the 5’ cap.

 

Coding Sequence (CDS)

Description: Sequence translated by the ribosomes, beginning with a start codon, and ending with a stop codon. Also known as the open reading frame (ORF).

Function in the cytosol: The CDS encodes the amino acid sequence of the protein.

Considerations for therapies: Codon optimization of the CDS can enhance protein expression. Due to redundancy in the genetic code, multiple codons can specify the same amino acid. However, synonymous codes are typically used at unequal frequencies in a cell, and this bias varies between species. Protein expression can suffer if the CDS contains codons that are rarely used by the host cell - for example, due to a low concentration of the matching tRNA in the cytosol. Codon optimization tools are available which replace lower-frequency codons (based on the target organism) and minimize secondary structure that can impede translation - all without affecting the amino acid sequence.

 

3’ Untranslated Region (3’ UTR)

Description: Sequence between the stop codon and poly(A) tail.

Function in the cytosol: The 3’ UTR influences the stability of the transcript.

Considerations for therapies: As with the 5’ UTR, sequences from the alpha and beta globins are widely used for the 3’ UTR of therapeutic mRNAs. These sequences bind to proteins that enhance the transcript’s stability by deterring degradation of the poly(A) tail3.

 

Poly(A) Tail

Description: Polyadenylation at the 3’ end of the mRNA.

Function in the cytosol: The poly(A) tail regulates mRNA stability and promotes initiation of translation. It recruits poly(A) binding protein (PABP) which protects the transcript from 3’ to 5’ nuclease degradation. PABP also interacts with initiation factors at the 5’ end to trigger protein synthesis.

Considerations for therapies: Longer poly(A) tails generally confer greater stability to the transcript; the optimal length is 100-150 bases2. For in vitro mRNA preparation, a poly(A) tail can be generated by two methods:

  1. Enzymatic polyadenylation of the mRNA after in vitro transcription
  2. Incorporation of the poly(A) sequence in the DNA template prior to transcription

The latter method produces a more uniform length and enables better batch control of the product3. The downside is that poly(A) sequences greater than 120 bp can be unstable in plasmids: truncations during amplification in bacteria are common4,5. As a result, DNA templates may contain shorter and more heterogeneous poly(A) tails, which in turn makes mRNA products less stable and protein expression more variable. Using optimized DNA preparation protocols or segmenting poly(A) regions with short spacers5 can increase the stability of these sequences in plasmids.

For quality control, the poly(A) sequence should be verified by Sanger sequencing after final plasmid preparation to check for truncations and mixed populations. As the therapy advances in development and production is scaled up, full-length RNA sequencing can be used to thoroughly characterize the mRNA product, including the length distribution of poly(A) tails.

 

Pseudouridine Modification

Replacing uridine with pseudouridine (Ψ), an isomer with the same base-pairing properties, has been shown to reduce immunogenicity and increase the stability of mRNA therapies. Pseudouridine helps mRNA evade the immune system and increases protection against nucleases. It can be added to in vitro transcription reactions in form of ΨTP. Use of a modified pseudouridine contributed to the success of the mRNA COVID vaccines developed by Pfizer-BioNTech and Moderna Therapeutics6.

 

Conclusion

An ideal mRNA for therapeutic applications is optimized, from end to end, for efficient translation and enhanced stability. Once inside the cell, each mRNA component plays a critical role in producing strong protein expression.

Manufacturing well-designed mRNA in a fast, scalable, and reliable manner can be difficult if the entire production process is not robust or efficient. Read our tech note to learn how Azenta Life Sciences integrates gene synthesis and in vitro transcription to deliver high-quality mRNA. Also, we can help you design the 5’ cap, UTRs, and poly(A) tail of your mRNA construct as part of a pilot project.

 

Download Tech Note

 

References

1. Sikorski, P. J. et al. The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5′ cap modulates protein expression in living cells. Nucleic Acids Research vol. 48 1607–1626 (2020).
2. Kwon, S., Kwon, M., Im, S., Lee, K. & Lee, H. mRNA vaccines: the most recent clinical applications of synthetic mRNA. Archives of Pharmacal Research vol. 45 245–262 (2022).
3. Kwon, H. et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials vol. 156 172–193 (2018).
4. Grier, A. E. et al. pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences. Molecular Therapy - Nucleic Acids vol. 5 e306 (2016).
5. Trepotec, Z., Geiger, J., Plank, C., Aneja, M. K. & Rudolph, C. Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life. RNA vol. 25 507–518 (2019).
6. Morais, P., Adachi, H. & Yu, Y.-T. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Frontiers in Cell and Developmental Biology vol. 9 (2021).

  • Genomics
  • Gene Synthesis
  • Sequencing
  • Cell & Gene Therapy
  • Vaccine
Home
Facebook twitter youtube linkedin
Copyright © 2023 Azenta US, Inc.

Footer menu

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Terms of Use
  • Careers
  • Subscribe